Market Research Outlook · Standards
Every fact on our trackers, calendars and briefs is checked against a primary record before it is published. This page explains what we accept as evidence, how we separate fact from our own view, and what we have corrected.
What counts as evidence
- Court orders and Patent Office decisions for patent numbers, expiry dates, injunctions and revocations.
- Regulator records for approvals and trial clearances, including CDSCO expert committee minutes and the National List of Essential Medicines.
- Company filings and launch announcements for launch dates, brands and launch prices.
- Government statements for programmes, schemes and national lists.
If a fact cannot be traced to one of these, it is not published. We do not hedge an unconfirmed claim; we leave it out until it is confirmed.
What we do not use
We do not republish market size, sales or prescription estimates produced by other research firms. Where no official source publishes a number, our pages say so.
Fact and view are kept apart
Paragraphs marked MRO View are our analysis. Everything outside them is a verified fact. A recommendation by a regulator’s expert committee is reported as a recommendation, not as a final approval.
How often we review
- India Drug Market Entry Tracker and India Drug Patent Expiry Calendar: monthly, and within a week of any launch or court ruling we follow.
- CDSCO Decoded: monthly, after committee minutes are released.
- Market entry briefs: updated once after the first launches, free for buyers.
Each page shows a Last reviewed date.
What we offer
| Product | What it answers | Price |
|---|---|---|
| Trackers, calendar and CDSCO Decoded | Who can sell what, from when, and what regulators just cleared | Free |
| Market entry brief, for example ruxolitinib | Should we launch this molecule in India, and how | USD 750 |
| Market report | How big is this market, who leads it and where it is going | USD 2,400 country, USD 3,000 regional, USD 3,500 global |
| Custom study | Your molecule, your competitors, your launch plan | Quoted per project |
Corrections log
| Date | Page | Correction |
|---|---|---|
| 17 Nov 2026 | Drug Market Entry Tracker | Linagliptin moved from Off patent to Generics launched; generic brands launched after the August 2023 expiry. Count of molecules with Indian generics or biosimilars corrected from 16 to 17. |
| 17 Nov 2026 | Drug Market Entry Tracker | Tirzepatide: an unconfirmed approval date removed; launch, KwikPen and second brand dates corrected. |
| 17 Nov 2026 | Drug Market Entry Tracker | Sacubitril with valsartan: first generic launch price range corrected to Rs 19 to Rs 45 a tablet; an unconfirmed partner brand removed; the September 2025 revocation dated and the patent number added. |
| 17 Nov 2026 | Drug Market Entry Tracker | Ranibizumab: number of approved biosimilars corrected to five; an unconfirmed trial size removed. |
| 17 Nov 2026 | Drug Market Entry Tracker | Maker names that could not be confirmed removed for semaglutide, empagliflozin, vildagliptin, insulin glargine, sofosbuvir, palbociclib and bedaquiline; confirmed brands added. |
| 17 Nov 2026 | Drug Market Entry Tracker | Osimertinib: an unconfirmed approval date removed; Indian patent number and term to 2032 added. Denosumab: Intas review date corrected to June 2025. |
Spotted something we should check?
Tell us and we will review it against the primary record within a week.